Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study
- 20 October 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (30) , 7546-7554
- https://doi.org/10.1200/jco.2005.05.525
Abstract
Prostate growth and differentiation are under androgenic control, and prior studies suggested that tumors that develop in hypogonadal men are more aggressive. We examined whether prostate weight was associated with tumor grade, advanced disease, or risk of biochemical progression after radical prostatectomy (RP). We evaluated the association of prostate weight with pathologic tumor grade, positive surgical margins, extracapsular disease, and seminal vesicle invasion using logistic regression and with biochemical progression using Cox proportional hazards regression among 1,602 men treated with RP between 1988 and 2003 at five equal-access medical centers, which composed the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. In outcome prediction models including multiple predictor variables, it was found that the predictor variable of prostate weight was significantly inversely associated with the outcomes of high-grade disease, positive surgical margins, extracapsular extension (all P ≤ .004), and biochemical progression (comparing prostate weight < 20 v ≥ 100 g: relative risk = 8.43; 95% CI, 2.9 to 24.0; P < .001). Similar associations were seen between preoperative transrectal ultrasound–measured prostate volume and high-grade disease, positive surgical margins, extracapsular extension (all P ≤ .005), seminal vesicle invasion (P = .07), and biochemical progression (P = .06). Men with smaller prostates had more high-grade cancers and more advanced disease and were at greater risk of progression after RP. These results suggest that prostate size may be an important prognostic variable that should be evaluated for use pre- and postoperatively to predict biochemical progression.Keywords
This publication has 44 references indexed in Scilit:
- SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, 2004
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Hormonal, cellular, and molecular control of prostatic developmentDevelopmental Biology, 2003
- The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasisBJU International, 2002
- Lower Prostate Specific Antigen Outcome Than Expected Following Radical Prostatectomy in Patients With High Grade Prostate and a Prostatic Specific Antigen Level of 4 Ng/Ml. or LessJournal of Urology, 2002
- Low Serum Testosterone and a Younger Age Predict for a Poor Outcome in Metastatic Prostate CancerAmerican Journal of Clinical Oncology, 1997
- Serum testosterone—A significant determinant of metastatic relapse for irradiated localized prostate cancerUrology, 1997
- Effect of flutamide and flutamide plus castraton on prostate size in patients with previously untreated prostate cancerUrology, 1996
- Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate CancerJAMA, 1991
- Changes in Dihydrotestosterone Metabolism Associated with the Development of Canine Benign Prostatic Hyperplasia*Endocrinology, 1981